echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The National Health Insurance Administration issued a list of 500 varieties, 2022 all completed with the amount!

    The National Health Insurance Administration issued a list of 500 varieties, 2022 all completed with the amount!

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: with volume procurement, this best use of the price-cutting sharp instrument on the industry's big action to come! !---- and volume purchase, this best-use price-cutting sharp stakes on the industry's big action to come! Today a message in the pharmaceutical circle quickly spread, the news said that the State Health Insurance Bureau has sent to the provincial health insurance bureaus a volume of procurement varieties catalog, a total of 500 varieties, its selection criteria for the procurement amount of order, covering the first 80% of the drugs, that is, are widely used in clinical, high sales of large varietiesAt the same time in the volume of procurement of the category, as long as the purchase amount of the first 80% of the varieties, chemical drugs, biological agents, traditional Chinese medicine should be included in the volume of procurementFor the 500 large varieties in the catalog, if the national belt procurement standards, then the state organization of the volume procurement, follow-up Shanghai will lead the national organization of drug tape procurement normalizationIf not in line with the scope of national belt procurement, the national belt procurement after the remaining varieties, provinces and cities can be combined with the local situation to determine the varieties and quantities, the selection criteria are: unrated varieties, clinical sales, mature varieties, as well as generic drugs larger than three varietiesThis year, all provinces to start a round of drug volume procurement, currently only 19 provinces carried out the volume of procurement, the meeting urged other provinces to act urgently, at the same time will be informed later, at the same time the State Council will be timely supervisionIn terms of time, 250 varieties will be covered by 2021 and all will be covered by 2022The 500 varieties that account for 80% of clinical sales will be purchased in volume, a figure that demonstrates the country's determination to reduce pricesNational belt has covered more than 100 varieties, the provinces need not worry about the current band volume flow label, the national belt procurement has been carried out two batches of three times, will be carried out the third batch, the first batch of 25 varieties, the second batch of 32 varieties, recently the Shanghai Joint Procurement Office issued 56 varieties, 86 product rules collection notice, the third batch is almost 56 varietiesWell, 113 varieties were carried out in these three batchesAccording to the list of 500 belt-volume procurement varieties circulated, the 113 varieties purchased by the state have been included, so if 250 varieties are to be covered by 2021, in the current situation, there are more than 100 varieties to be the provinces themselvesOf course, given the progress of the consistency evaluation, the number of self-volume purchases that provinces need to do on their own may not be as highHowever, because this list is high sales, occupy more medical insurance costs, commonly used varieties, so the provinces of the belt procurement is mainly targeted at the unrated, exclusive varieties, such as the provinces sales ranking, must go through a round of price reductionFor such varieties, how to find a balance between price reduction and ensuring clinical supply is a difficult point for provincial-level volume procurementFor example, in Qinghai Province recently carried out the results of the band procurement, there are competing varieties can still carry out band procurement, but for some exclusive varieties, the final winning bid results show that only the limit price does not take the amountObviously, the results of the price reduction negotiations on the latter is not ideal, in the absence of an ideal reduction, can only limit the price of the net, return to the old roadAnd this situation is obviously also expected by the National Health Insurance Administration, the National Health Insurance Administration said: the provinces do not worry about the flow of labels, flow-standard products reported to the National Health Insurance Administration in a timely manner, further study the reasonsTherefore, pharmaceutical companies must do a good job of price reduction expectations, the provinces to give the amount, must come up with a real knife real gun price reduction range, at least let the local satisfaction of the decline Otherwise, if you don't cooperate with the policy, it will rise to the National Health Insurance Administration, where anything can escalate in the face of a crackdown on commercial bribery Marketing must be fast, high efficiency of 500 species accounting for 80% of clinical sales to carry out band procurement, which will undoubtedly have a shock to the industry will be huge and disruptive, which put forward higher requirements for marketing: whether generic or patented drugs, marketing efficiency must be higher, faster, more cost-effective For generics, band purchases are becoming the norm, as long as the band standard is met Even if there is less competition now, the bid can be won at a high price, but the winning cycle is only one year, the second year will follow At the pace of the new review, competitors will emerge quickly and competitive advantage will be difficult to last This means that in the future, as long as the expired patent edifying drugs, whether high-end or low-end, will be with the national and provincial and municipal levels at all levels of the volume of procurement step by step to become a generic drug, profit margins will be smaller year by year What pharmaceutical companies need to do is to have as much profit margin as possible The same is true for innovative medicines Health insurance negotiations give innovative drugs an annual market entry opportunity, when the choice of price reduction to enter the market, how to enlarge the market during the effective access period is all pharmaceutical companies must do When generics become genericdrugs, all pharmaceutical companies will keep a close eye on high-margin products, and the competition for innovative drugs will be fierce Abitron, which went public in 2016 and negotiated access to health insurance in 2017, was included in the collection when the market increased to 900 million, and four years after listing, the price dropped to 7.6% of the price at the start of the listing; Pfizer's Tofateb was approved for sale in 2017, negotiating health insurance in 2019, an increase of 423% over the year, but at the same time, domestic generic drugs have been approved, and this year Tofab has entered the third batch of purchases Another typical example is that, in just a few years, due to the influx of belt manufacturers, the hot PD-1 because of the competition is very fierce, now it is almost into a universal medicine What should pharmaceutical companies do under the new pharmaceutical marketing? Wang Peng, vice president of the drug line, said that the Internet has a strong connectivity function, can connect manufacturers, representatives and doctors, patients, from the representative to the customer every step of the action for effective data collection, after data collection, there is a strong resource integration and data mining function, can be on the drug generation every action can be data production, analysis, feedback, so that the Internet becomes a new tool for pharmaceutical marketing upgrade In addition, he said, the essence of academic promotion is the transmission of medical information, improve the efficiency and effectiveness of information transmission is the advantages of the Internet The fun academic system introduced by Pharmaceutical Sincoma helps pharmaceutical companies to do academic promotion, with the help of Internet technology, pharmaceutical companies in the end of academic promotion to achieve standardized dissemination Fun academic system by representing the two ends of the connection of pharmaceutical companies and users, so that customers accept that information is a unified production of pharmaceutical companies, do not worry about the lack of representative information transmission, to ensure the standardization of information transmission at the final end In addition, delegates can use 10 days to open 30 sessions, equivalent to 10 times the previous efficiency, can help drug companies to achieve rapid coverage, in addition to data buried points, effectively assess the effect of the delivery to doctors
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.